Ceramides and cardiac function in children with chronic kidney disease

Pediatric Nephrology

Volumn 29, Issue 3, 2014, Pages 415-422

  Mitsnefes, Mark ^a   Scherer, Philipp E ^b   Friedman, Lisa Aronson ^c   Gordillo, Ruth ^b   Furth, Susan ^d   Warady, Bradley A ^e  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Ceramides; CKD; Heart; Heart failure; Lipids; Sphingolipids

Indexed keywords

ADOLESCENT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CERAMIDES; CHILD; CHILD, PRESCHOOL; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INFANT; LACTOSYLCERAMIDES; LINEAR MODELS; MALE; MULTIVARIATE ANALYSIS; MYOCARDIAL CONTRACTION; NORTH AMERICA; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84894231372     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-013-2642-1     Document Type: Article

References (23)

1. Shlipak MG, Lash JP, Yang W, Teal V, Keane M, Cappola T, Keller C, Jamerson K, Kusek J, Delafontaine P, He J, Miller ER 3rd, Schreiber M, Go AS, Investigators CRIC (2011) Symptoms characteristic of heart failure among CKD patients without diagnosed heart failure. J Card Fail 17:17-23
2. Hammad SM (2011) Blood sphingolipids in homeostasis and pathobiology. Adv Exp Med Biol 721:57-66
3. Park TS, Hu Y, Noh HL, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang XC, Abel ED, Goldberg IJ (2008) Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 49:2101-2112
4. Furth SL, Cole SR, Moxey-Mims M, Kaskel F, Mak R, Schwartz G, Wong C, Muñoz A, Warady BA (2006) Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study. Clin J Am Soc Nephrol 1:1006-1015
5. Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629-637
6. Mitsnefes M, Flynn J, Cohn S, Samuels J, Blydt-Hansen T, Saland J, Kimball T, Furth S, Warady B, CKiD Study Group (2010) Masked hypertension and associated left ventricular hypertrophy in children with CKD. J Am Soc Nephrol 21:137-144
7. Khoury PR, Mitsnefes M, Daniels SR, Kimball TR (2009) Age-specific reference intervals for indexed left ventricular mass in children. J Am Soc Echocardiogr 22:709-714
8. Shimizu G, Zile MR, Blaustein AS, Gaash WH (1985) Left ventricular chamber filling and midwall fiber lengthening in patients with left ventricular hypertrophy: overestimation of fiber velocities by conventional midwall measurements. Circulation 71:266-272 (Pubitemid 15157086)
9. De Simone G, Devereux RB, Koren MJ, Menash GA, Casale PN, Laragh JH (1996) Midwall left ventricular mechanics. An independent predictor of cardiovascular risk in arterial hypertension. Circulation 93:259-265 (Pubitemid 26031483)
10. Hammad SM, Pierce JS, Soodavar F, Smith KJ, Al Gadban MM, Rembiesa B, Klein RL, Hannun YA, Bielawski J, Bielawska A (2010) Blood sphingolipidomic in healthy humans: impact of sample collection methodology. J Lipid Res 51:3074-3087
11. Shaner RL, Allegood JC, Park H, Wang E, Kelly S, Haynes CA, Sullards MC, Merrill AH Jr (2009) Quantitative analysis of sphingolipids for lipidomics using triple quadrupole and quadrupole linear ion trap mass spectrometers. J Lipid Res 50:1692-1707
12. Schwartz GJ, Schneider MF, Maier PS, Moxey-Mims M, Dharnidharka V, Warady BA, Furth SL, Muñoz A (2012) Improved equations estimating GFR in children with chronic kidney disease using an immunonephelometric determination of cystatin C. Kidney Int 82:445-453
13. Boon J, Hoy AJ, Stark R, Brown RD, Meex RC, Henstridge DC, Schenk S, Meikle PJ, Horowitz JF, Kingwell BA, Bruce CR, Watt MJ (2013) Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 62:401-410
14. Saland JM, Pierce CB, Mitsnefes MM, Flynn JT, Goebel J, Kupferman JC, Warady BA, Furth SL (2010) Dyslipidemia in children with chronic kidney disease. Kidney Int 78:1154-1163
15. Swynghedauw B (1999) Molecular mechanisms of myocardial remodeling. Physiol Rev 79:215-262 (Pubitemid 29056953)
16. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH (2000) Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci USA 97:1784-1789 (Pubitemid 30118520)
17. Yagyu H, Chen G, Yokoyama M, Hirata K, Augustus A, Kako Y, Seo T, Hu Y, Lutz EP, Merkel M, Bensadoun A, Homma S, Goldberg IJ (2003) Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest 111:419-426 (Pubitemid 36182219)
18. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K, Noon GP, Frazier OH, Taegtmeyer H (2004) Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 18:1692-1700 (Pubitemid 39463708)
19. Zhao H, Przybylska M, Wu IH, Zhang J, Siegel C, Komarnitsky S, Yew NS, Cheng SH (2007) Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56:1210-1218 (Pubitemid 46715599)
20. Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE (2013) Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab 24:1-4
21. Chatterjee S, Pandey A (2008) The Yin and Yang of lactosylceramide metabolism: implications in cell function. Biochim Biophys Acta 1780:370-382
22. Chatterjee S, Alsaeedi N (2012) Lactosylceramide synthase as a therapeutic target to mitigate multiple human diseases in animal models. Adv Exp Med Biol 749:153-169
23. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL (1996) Basic mechanisms in heart failure: the cytokine hypothesis. J Card Fail 2:243-249